Correspondence 0001104659-23-078761 from Acurx Pharmaceuticals, Inc. (ACXP)

Acurx Pharmaceuticals, Inc.
Date: July 6, 2023 · CIK: 0001736243 · Accession: 0001104659-23-078761

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-273015

Date

July 6, 2023

Author

David P. Luci

Form

CORRESP

Company

Acurx Pharmaceuticals, Inc.

Letter

VIA EDGAR Division of Corporation Finance Attention: Alan Campbell Re: Acurx Pharmaceuticals, Inc. Registration Statement on Form S-1 File No. 333-273015 Request for Acceleration

Dear Mr. Campbell:

Pursuant to Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, Acurx Pharmaceuticals, Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-273015), so that it may become effective at 5:00 p.m. (Washington, D.C. time) on July 10, 2023, or as soon thereafter as practicable.

Please call Ivan K. Blumenthal or Jeffrey D. Cohan of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Registrant, at (212) 692-6784 or (212) 692 6710 with any comments or questions regarding this matter.

Very truly yours,
Acurx Pharmaceuticals, Inc.

Show Raw Text

CORRESP
1
filename1.htm

Acurx Pharmaceuticals, Inc.

259 Liberty Avenue

Staten Island, New York 10305

July 6, 2023

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attention: Alan Campbell

    Re:
    Acurx Pharmaceuticals, Inc.

    Registration Statement on Form S-1

    File No. 333-273015

    Request for Acceleration

Dear Mr. Campbell:

Pursuant to Rule 461 of Regulation
C promulgated under the Securities Act of 1933, as amended, Acurx Pharmaceuticals, Inc. (the “Registrant”) hereby requests
acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-273015), so that it may become effective at
5:00 p.m. (Washington, D.C. time) on July 10, 2023, or as soon thereafter as practicable.

Please call Ivan K. Blumenthal
or Jeffrey D. Cohan of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Registrant, at (212) 692-6784 or (212) 692
6710 with any comments or questions regarding this matter.

    Very truly yours,

    Acurx Pharmaceuticals, Inc.

    By:
    /s/ David P. Luci

    Name: David P. Luci

    Title:   President and Chief Executive Officer

    cc:
    Acurx Pharmaceuticals, Inc.

    David P. Luci

    Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

    Ivan K. Blumenthal, Esq.

    Jeffrey D. Cohan, Esq.

SecProbe.io